(ALBPS) – Press Releases
-
Biophytis to Restate Previously Issued Financial Statements
-
Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia
-
Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million
-
Biophytis Announces Promising Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) S
-
Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September
-
Biophytis Reports H1 2021 Financial Results and Provides Business Update
-
Biophytis Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 COVA Study With Sarconeos (BIO101) in COVID-19
-
Biophytis to Attend Key Upcoming Investor Events and Industry Conferences
-
Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment
-
Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19
-
Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021
-
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
-
Judgment Rendered on July 16, 2021 in the Proceedings Between Biophytis and Negma Group Ltd by the Execution Judge From the Paris Court of Justice
-
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
-
Biophytis Reinforces Leadership Teams with Three Senior Appointments
-
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
-
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
-
Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
-
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
-
BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021
-
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
-
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD
-
Biophytis - Convening of Another Combined General Meeting at a Later Date
-
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021
-
BIOPHYTIS Identifies False Report Regarding COVA study
-
BIOPHYTIS Gives Updates on its Phase 2-3 COVA Study on COVID-19
-
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis Against Negma Group Ltd
-
Biophytis’ Combined Annual General Meeting Will Take Place on April 26, 2021 behind closed doors
-
Biophytis Reports 2020 Full Year Results
-
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities Approvals in France and Belgium
-
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
-
Biophytis Announces Trading Resumption of its Ordinary Shares and Share Warrants on Euronext Growth
-
Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth
-
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market
-
Biophytis Announces the Launch of its Proposed Public Offering and Nasdaq Listing
-
Biophytis Announces the Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”)
-
Biophytis Announces Public Filing of a Registration Statement for Proposed Initial Public Offering in the United States
-
Biophytis Announces Plan to Publicly File Later Today Registration Statement for Proposed Initial Public Offering in the United States
-
BIOPHYTIS receives DMC recommendation for starting recruitment for Part 2 of its Phase 2-3 COVA study in COVID-19
-
Biophytis Enrolls First Patient in Brazil in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure
-
Biophytis announces a € 10 million capital increase through private placement
-
Biophytis Announces a € 6.1 Million Capital Increase Through Private Placement
-
Biophytis Receives FDA IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure
-
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer
-
Biophytis Announces Results of 2019 Annual General Meeting of Shareholders
-
Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon)
-
Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer
-
Biophytis Announces Publication of its 2018 Annual Report
-
Biophytis Files Registration Statement for Proposed Initial Public Offering in the United States
-
Biophytis Reports Annual 2018 Financial Results and Provides Operational Update
Back to ALBPS Stock Lookup